title: Topical brimonidine tartrate 0·33% gel effectively reduces the post-treatment erythema of daylight-activated photodynamic therapy.
authors.affiliation: Department of Dermatology, Heinrich Heine University, Moorenstraße 5, 40225, Düsseldorf, Germany. peterarne.gerber@med.uni-duesseldorf.de.
authors.forename: P A
authors.identifier: http://orcid.org/0000-0003-1657-1863
authors.initials: PA
authors.lastname: Gerber
mesh_terms: D000279:Administration, Cutaneous; D058647:Adrenergic alpha-2 Receptor Agonists / Q000008:administration & dosage*; D000328:Adult; D000068438:Brimonidine Tartrate / Q000008:administration & dosage*; D003875:Drug Eruptions / Q000209:etiology*; D004890:Erythema / Q000188:drug therapy* / Q000209:etiology; D005148:Facial Dermatoses / Q000188:drug therapy*; D005782:Gels; D006801:Humans; D008297:Male; D010778:Photochemotherapy / Q000009:adverse effects*; D012393:Rosacea / Q000188:drug therapy; D013472:Sunlight
chemical_list: D058647:Adrenergic alpha-2 Receptor Agonists; D005782:Gels; D000068438:Brimonidine Tartrate